Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quest Diagnostics Introduces bioMerieux THxID®-BRAF Test

Published: Wednesday, June 11, 2014
Last Updated: Wednesday, June 11, 2014
Bookmark and Share
A companion diagnostic to advance precision medicine for melanoma.

Quest Diagnostics has introduced a new cancer test service based on the FDA-approved THxID®-BRAF test from bioMerieux, a world leader in the field of in vitro diagnostics. The THxID®-BRAF test is a companion diagnostic for two treatments for melanoma.

The test is intended to be used as an aid in selecting patients with melanoma whose tumors carry the BRAF V600E mutation for treatment with dabrafenib [Tafinlar®] and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib [Mekinist™].

The U.S. Food and Drug Administration approved the two drugs and the gene test as a companion diagnostic in May 2013. The drugs, manufactured by GlaxoSmithKline, treat patients with advanced (metastatic) or unresectable (cannot be surgically removed) melanoma, the most dangerous type of skin cancer. bioMerieux manufactures the THxID-BRAF test kit.

Dermatologists, oncologists, hospital pathologists and other physicians may order the test through Quest Diagnostics, including its AmeriPath and Dermpath businesses, which specialize in anatomic and dermatologic pathology testing.

"Because of this relationship with Quest, many more doctors will have access to THxID®-BRAF test. This means that more patients with advance melanoma will benefit from the optimized treatment that results when the THxID®-BRAF test is used in designing their regimens," said Dr. Samuel Bozzette, Vice President, Medical Affairs - Americas, bioMerieux, Inc.

"The addition of the THxID-BRAF test to our menu reflects our commitment to offering the most advanced dermatopathology testing available and to the field of precision medicine, which aims to improve outcomes based on a holistic clinical understanding of the patient," said Frederic Waldman MD, PhD, medical director, cancer diagnostics, Quest Diagnostics. "The THxID-BRAF test further extends the services we provide for melanoma and other cancers across a continuum of care, giving physicians insights to help guide treatment decisions and empower better health."

"Because Quest reaches about half of the practicing physicians and hospitals in the United States, patients and providers will now have access to the THxID-BRAF test on a truly broad national scale," added Dr. Waldman.

In addition to the bioMerieux test, Quest offers the FDA-cleared cobas® 4800 BRAF V600 Mutation Test, which detects the BRAF V600E mutation in order to help physicians select patients for treatment with vemurafenib, an oral medicine designed to treat patients whose melanoma tumors harbor the mutation. Quest also offers a laboratory-developed test for assessing BRAF mutations in melanoma, thyroid, and colorectal cancers based on sanger sequencing.

BRAF is a gene implicated in several cancers, including melanoma. Approximately half of melanomas arising in the skin have a BRAF gene mutation.

Melanoma is the leading cause of death from skin disease. The National Cancer Institute estimates 76,100 Americans will be diagnosed with melanoma and 9,710 will die from the disease in 2014.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quest Diagnostics Sponsors Women's Health Movement
Company offers 10,000 vouchers for free wellness screenings as national presenting sponsor.
Wednesday, May 02, 2012
New York State Approves Quest Diagnostics' Fragile X Syndrome Test
XSense® is said to be the first laboratory test that may be suitable for population-based screening for Fragile X Syndrome.
Friday, July 30, 2010
Quest Diagnostics Launches Test to Predict Risk of Breast Cancer Recurrence in Women
Quest Diagnostics has introduced a test which can help physicians to predict the risk of disease recurrence in women with ER-positive, lymph node-negative breast cancer.
Tuesday, December 19, 2006
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Genetic Tug of War
Researchers have reported on a version of genetic parental control in mice that is more targeted, and subtle than canonical imprinting.
Error Correction Mechanism in Cell Division
Cell biologists have reported an advance in understanding the workings of an error correction mechanism that helps cells detect and correct mistakes in cell division early enough to prevent chromosome mis-segregation and aneuploidy, that is, having too many or too few chromosomes.
How to Become a Follicular T Helper Cell
Uncovering the signals that govern the fate of T helper cells is a big step toward improved vaccine design.
Researchers Resurrect Ancient Viruses
Researchers at Massachusetts Eye and Ear and Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina.
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!